NASDAQ:ISPC

iSpecimen (ISPC) Stock Forecast, Price & News

$0.67

-0.05 (-6.94%)

(As of 09/21/2023 ET)

Compare

Today's Range: $0.66
▼
$0.72
50-Day Range: $0.62
▼
$1.69
52-Week Range: $0.61
▼
$2.58

Volume: 12,699 shs
Average Volume: 27,536 shs
Market Capitalization: $6.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.63

iSpecimen MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,037.9% Upside
$7.63 Price Target
Short Interest: Healthy
0.27% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$12,960 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
iSpecimen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.63, iSpecimen has a forecasted upside of 1,037.9% from its current price of $0.67.
Amount of Analyst Coverage
iSpecimen has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.27% of the float of iSpecimen has been sold short.
Short Interest Ratio / Days to Cover
iSpecimen has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in iSpecimen has recently decreased by 45.42%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
iSpecimen does not currently pay a dividend.
Dividend Growth
iSpecimen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ISPC.

2.8

News and Social Media Coverage

News Sentiment
iSpecimen has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for iSpecimen this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, iSpecimen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,960.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
32.70% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.61% of the stock of iSpecimen is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of iSpecimen is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of iSpecimen is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
iSpecimen has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About iSpecimen (NASDAQ:ISPC) Stock

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

ISPC Price History

30 days | 90 days | 365 days | Advanced Chart

ISPC Stock News Headlines

September 16, 2023 | finance.yahoo.com

Insider Buying: Benjamin Bielak Acquires 18,000 Shares of iSpecimen Inc

September 13, 2023 | finance.yahoo.com

iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 7, 2023 | finance.yahoo.com

Biotech services company iSpecimen company lays off one-quarter of its staff

September 6, 2023 | msn.com

iSpecimen to lay off 20% of its employees as it seeks profitability

September 6, 2023 | finance.yahoo.com

iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability

August 30, 2023 | finance.yahoo.com

iSpecimen Launches New Virtual Cancer Sequencing Procurement Program

August 16, 2023 | finance.yahoo.com

iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 9, 2023 | finance.yahoo.com

iSpecimen Introduces New Marketplace Functionality to Streamline Access to Clinical Remnant Samples for Researchers

August 7, 2023 | finance.yahoo.com

One iSpecimen Inc. (NASDAQ:ISPC) Analyst Just Made A Major Cut To Next Year's Estimates

August 2, 2023 | finance.yahoo.com

iSpecimen Reports Second Quarter 2023 Financial and Operating Results

July 25, 2023 | finance.yahoo.com

iSpecimen to Report Second Quarter 2023 Results on August 2, 2023

July 6, 2023 | finance.yahoo.com

Thirteen New Biospecimen Suppliers Added to iSpecimen’s Proprietary Provider Network

May 23, 2023 | finance.yahoo.com

iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023

May 18, 2023 | msn.com

Looking Into iSpecimen's Return On Capital Employed

May 4, 2023 | finance.yahoo.com

iSpecimen Reports First Quarter 2023 Results

April 24, 2023 | finance.yahoo.com

iSpecimen to Participate in the Aegis Virtual Conference on May 4, 2023

April 20, 2023 | finance.yahoo.com

iSpecimen to Report First Quarter 2023 Results on May 4, 2023

April 18, 2023 | finance.yahoo.com

Market Might Still Lack Some Conviction On iSpecimen Inc. (NASDAQ:ISPC) Even After 33% Share Price Boost

March 17, 2023 | finance.yahoo.com

iSpecimen Inc. (NASDAQ:ISPC) Q4 2022 Earnings Call Transcript

March 14, 2023 | finance.yahoo.com

iSpecimen Reports Full Year 2022 Results

March 14, 2023 | msn.com

iSpecimen's Earnings: A Preview

March 2, 2023 | finance.yahoo.com

iSpecimen Named to Fast Company’s World’s Most Innovative Companies Annual List for 2023

March 1, 2023 | finance.yahoo.com

iSpecimen to Report Fourth Quarter and Full Year 2022 Results on March 14, 2023

February 8, 2023 | finance.yahoo.com

iSpecimen Expands Biospecimen Provider Network

January 24, 2023 | finance.yahoo.com

iSpecimen Appoints Eric Langlois as Chief Revenue Officer

See More Headlines

Receive ISPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter.

ISPC Company Calendar

Last Earnings: 8/02/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ISPC
CUSIP: N/A
CIK: 1558569
Web: ispecimen.com
Phone: 781-301-6700
Fax: N/A
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.63
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $4.25
Forecasted Upside/Downside: +1,037.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,250,000.00
Net Margins: -110.39%
Pretax Margin: -110.39%
Return on Equity: -59.17%
Return on Assets: -48.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.84
Quick Ratio: 3.84

Sales & Book Value

Annual Sales: $10.40 million
Price / Sales: 0.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.32 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 9,070,000
Free Float: 6,101,000
Market Cap: $6.08 million
Optionable: Not Optionable
Beta: 2.02

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Ms. Tracy Wilson Curley (Age 61)
CEO, CFO, Treasurer & Director
Comp: $313.38k

Mr. Benjamin Bielak (Age 53)
Chief Information Officer
Comp: $307.94k

Ms. Dawn Michelle
VP of Operations

Ms. Carly Lejnieks
VP of Marketing

Ms. Annette Arnold
VP of Sales & Bus. Devel.

Mr. David Wages M.D.
Ph.D., Chief Medical Officer

Mr. Eric Langlois
Chief Revenue Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ISPC Stock - Frequently Asked Questions

Should I buy or sell iSpecimen stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iSpecimen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ISPC shares.
View ISPC analyst ratings or view top-rated stocks.
What is iSpecimen's stock price forecast for 2023?: 1 brokers have issued 12-month price objectives for iSpecimen's shares. Their ISPC share price forecasts range from $4.25 to $11.00. On average, they predict the company's stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 1,037.9% from the stock's current price.
View analysts price targets for ISPC or view top-rated stocks among Wall Street analysts.
How have ISPC shares performed in 2023?: iSpecimen's stock was trading at $1.3750 at the beginning of 2023. Since then, ISPC stock has decreased by 51.3% and is now trading at $0.6701.
View the best growth stocks for 2023 here.
When is iSpecimen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ISPC earnings forecast.
How were iSpecimen's earnings last quarter?: iSpecimen Inc. (NASDAQ:ISPC) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.39) EPS for the quarter. The firm earned $1.63 million during the quarter. iSpecimen had a negative trailing twelve-month return on equity of 59.17% and a negative net margin of 110.39%.
When did iSpecimen IPO?: (ISPC) raised $20 million in an IPO on Thursday, June 17th 2021. The company issued 2,200,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is iSpecimen's stock symbol?: iSpecimen trades on the NASDAQ under the ticker symbol "ISPC."
Who are iSpecimen's major shareholders?: iSpecimen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.26%). Insiders that own company stock include Andrew L Ross, Benjamin Bielak and Tracy Curley.
View institutional ownership trends.
How do I buy shares of iSpecimen?: Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is iSpecimen's stock price today?: One share of ISPC stock can currently be purchased for approximately $0.67.
How much money does iSpecimen make?: iSpecimen (NASDAQ:ISPC) has a market capitalization of $6.08 million and generates $10.40 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.
How can I contact iSpecimen?: The official website for the company is ispecimen.com. The company can be reached via phone at 781-301-6700 or via email at ispecimen@kcsa.com.

This page (NASDAQ:ISPC) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial